Browse News
Filter News
Found 949 articles
-
One year and more than 410,000 deaths later, the United States is still firmly in the grips of the COVID-19 pandemic.
-
With the Pfizer-BioNTech and Moderna COVID-19 vaccines currently authorized in the U.S. and being distributed and dosed, some of the attention is shifting to Johnson & Johnson’s efforts for its one-shot vaccine.
-
Americans are still hesitant to be vaccinated against COVID-19, according to just-released research from Invisibly.
-
The decision was made based on an Independent Data Monitoring Committee recommendation which indicated the study was unlikely to meet its specified primary efficacy endpoint of progression-free survival.
-
Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda
1/21/2021
Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in the Phase 1/2 study of Moderna’s vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co., Ltd (NYSE: TAK). TAK-919 is Takeda’s development code for Moderna’s COVID-19 vaccine candidate.
-
Aviva Pharmacy Provides Initial Doses of COVID-19 Vaccine
1/21/2021
Aviva Pharmacy, an independent pharmacy located in Long Beach, CA has announced that it has obtained supplies of both the Moderna and Pfizer COVID-19 vaccines and has begun administering vaccinations to health care providers and those 65 years of age or older in Long Beach.
-
Rochelle Walensky, who most recently served as chief of the division of infectious diseases at Massachusetts General Hospital, will become the new head of the U.S. Centers for Disease Control and Prevention under the administration of Joe Biden.
-
NEUVOGEN's official strategy revolves around covering the entire immune system so that the tumor cannot perform an “immune escape”. Past immune priming efforts have fallen short because they focus on only a handful of important targets that some tumor cells may not express, thereby allowing them ...
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
-
One approach that is being developed by researchers at Stanford University leveraged nanoparticles. Preclinical research was recently published on it in the journal ACS Central Science.
-
Despite its lofty valuation, the company does not yet have any drugs in the clinic, although it expects to submit Investigational New Drug applications in 2022 and 2023.
-
Corona Virus Vaccines Market | Exclusive Report on the Current Scenario
1/18/2021
COVID-19 refers to a viral infection occurred due to a corona virus named SARS-CoV-2. This virus attacks the respiratory tract of an individual.
-
Zika Virus Vaccine Market: Preventive Segment to Witness Significant Growth
1/18/2021
Zika virus disease is caused by a virus transmitted primarily by Aedes mosquitoes, which bite during the day. It is also transmitted through sexual contact with an infected person or through an infected pregnant woman to the fetus.
-
Statement of the Federal-Provincial-Territorial Ministers of Health on COVID-19 Immunization
1/15/2021
- The Federal, Provincial and Territorial Ministers of Health today issued the following statement: Canada , the response to the COVID-19 pandemic is built on a solid foundation of collaboration. We are witnessing this spirit in real time as front line workers, Indigenous partners, and federal, provincial and territorial governmemt
-
Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days.
-
Oragenics Issues Letter to Stockholders
1/14/2021
Oragenics, Inc. (NYSE American: OGEN) today issued the following letter to stockholders from its President and Chief Executive Officer, Alan Joslyn, Ph.D.: To My Fellow Stockholders, With so much encouraging news recently around COVID-19 vaccine development, this is an excellent time to update
-
As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. FDA and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today.
-
Slaoui will stay on as an adviser for one month. His resignation from the vaccine program was made at the request of the incoming Biden administration.
-
Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.
-
Gilead is projecting remdesivir sales of about $2.825 billion alone for 2020.